SNY
Sanofi Healthcare - Pharmaceuticals Investor Relations →
Sanofi (SNY) closed at $43.08 as of 2026-07-31, trading 3.5% below its 200-week moving average of $44.66. This places SNY in the below line zone. The stock is currently moving closer to the line, down from -2.8% last week. The 14-week RSI sits at 45, indicating neutral momentum.
Trading volume is running at 1.6x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.13 ratio) is neutral — neither side is clearly dominating.
Over the past 1208 weeks of data, SNY has crossed below its 200-week moving average 20 times. On average, these episodes lasted 13 weeks. Historically, investors who bought SNY at the start of these episodes saw an average one-year return of +11.3%.
With a market cap of $103.2 billion, SNY is a large-cap stock. The company generates a free cash flow yield of 16.1%, which is notably high. Return on equity stands at 6.6%.
Over the past 23.2 years, a hypothetical investment of $100 in SNY would have grown to $344, compared to $1166 for the S&P 500. SNY has returned 5.5% annualized vs 11.2% for the index, underperforming the broader market over this period.
Free cash flow has been declining at a -5% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: SNY vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After SNY Crosses Below the Line?
Across 20 historical episodes, buying SNY when it crossed below its 200-week moving average produced an average return of +9.0% after 12 months (median +13.0%), compared to +13.5% for the S&P 500 over the same periods. 80% of those episodes were profitable after one year. After 24 months, the average return was +22.1% vs +34.5% for the index.
Each line shows $100 invested at the moment SNY crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices SNY would reach each dislocation threshold.
Dislocation Price Levels
Prices where SNY's Bean Score would hit each σ threshold. Valid until next earnings report (date TBD — last report: 2026-03-31).
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $41.38 | Unusually cheap — potential buy zone |
| Value | +1σ | $42.55 | Cheap vs. own history |
| Fair Value | +0σ | $43.78 | Historical mean behavior |
| Expensive | -1σ | $45.08 | Expensive vs. own history |
| Deep Expensive | -2σ | $46.46 | Unusually expensive — potential trim zone |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from SNY's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
SNY has crossed below its 200-week MA 20 times with an average 1-year return of +11.3% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jul 2003 | Sep 2003 | 5 | 6.3% | +21.2% | +272.3% |
| Jan 2008 | Sep 2009 | 86 | 35.7% | -21.7% | +136.4% |
| Feb 2010 | Feb 2010 | 1 | 1.4% | +2.1% | +144.8% |
| Apr 2010 | Sep 2010 | 21 | 13.9% | +22.2% | +154.8% |
| Nov 2010 | Jan 2011 | 7 | 2.4% | +3.5% | +156.5% |
| Nov 2015 | Mar 2017 | 71 | 15.8% | -0.5% | +57.4% |
| Apr 2017 | Apr 2017 | 1 | 0.8% | -6.4% | +47.3% |
| Dec 2017 | Jan 2018 | 4 | 1.6% | +5.6% | +45.4% |
| Jan 2018 | Jul 2018 | 22 | 10.6% | +5.2% | +45.5% |
| Mar 2020 | Mar 2020 | 1 | 7.2% | +36.2% | +51.1% |
| Aug 2022 | Nov 2022 | 15 | 14.9% | +25.2% | +15.8% |
| Oct 2023 | Nov 2023 | 3 | 7.0% | +31.3% | +14.8% |
| Dec 2023 | Dec 2023 | 1 | 0.3% | +9.1% | +6.9% |
| Feb 2024 | Feb 2024 | 2 | 1.7% | +19.6% | +6.4% |
| Apr 2024 | Apr 2024 | 2 | 2.6% | +16.9% | +7.8% |
| Sep 2025 | Sep 2025 | 1 | 1.3% | N/A | -0.2% |
| Jan 2026 | Jan 2026 | 1 | 0.1% | N/A | -2.4% |
| Feb 2026 | Feb 2026 | 1 | 1.4% | N/A | -1.2% |
| Mar 2026 | Mar 2026 | 3 | 6.6% | N/A | +2.1% |
| Apr 2026 | Ongoing | 14+ | 4.5% | Ongoing | -1.3% |
| Average | 13 | — | +11.3% | — |
Frequently Asked Questions
Is SNY below its 200-week moving average?
Yes. As of 2026-07-31, Sanofi (SNY) is trading 3.5% below its 200-week moving average of $44.66. The current price is $43.08.
What is SNY's 200-week moving average price?
Sanofi's 200-week moving average is $44.66 as of 2026-07-31. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when SNY drops below its 200-week moving average?
SNY has crossed below its 200-week moving average 20 times in our data. On average, buying at that moment produced a one-year return of +11.3%. These dips have historically been decent entry points. These episodes lasted 13 weeks on average.
Is SNY a good value right now?
Here's what our data says about SNY as of 2026-07-31: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 45. Free cash flow yield is 16.1%. Return on equity is 6.6%. This is not a buy or sell recommendation — always do your own research.
How does SNY compare to the S&P 500?
Over the past 23.2 years, $100 invested in SNY would have grown to $344, compared to $1166 for the S&P 500. That's 5.5% annualized vs 11.2% for the index. SNY has underperformed the broader market over this period.
Does SNY pay a dividend?
Yes. Sanofi currently pays a dividend yield of 561.00%.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-07-31